The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients.
Tamoxifen is a standard therapeutical treatment in patients with estrogen receptor positive breast carcinoma. However, less than 50% of estrogen receptor positive breast cancers do not respond to tamoxifen treatment whereas 40% of tumors that initially respond to treatment develop resistance over time. The underlying mechanisms for tamoxifen resistance are probably multifactorial but remain largely unknown. The primary aim of this study was to investigate the impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOH) and immunohystochemical expression of PTEN in 49 primary breast carcinomas of patients treated with tamoxifen as the only adjuvant therapy. The effect of PTEN inactivation on breast cancer progression and disease outcome was also analyzed. Reduced or completely lost PTEN expression was observed in 55.1% of samples, while 63.3% of samples displayed LOH of PTEN gene. Inactivation of PTEN immunoexpression significantly correlated with the PTEN loss of heterozygosity, suggesting LOH as the most important genetic mechanism for the reduction or complete loss of PTEN expression in primary breast carcinoma. Most importantly, LOH of PTEN and consequential reduction of its immunoexpression showed significant correlation with the recurrence of the disease. Besides, our study revealed that LOH of PTEN tumor suppressor was significantly associated with shorter disease free survival, breast cancer specific survival and overall survival. In summary, our results imply that LOH of PTEN could be used as a good prognostic characteristic for the outcome of breast cancer patients treated with tamoxifen.
Department of Neurobiology, Institute for Biological Research Sinisa Stankovic, University of Belgrade, Belgrade, Serbia. nikolata@ibiss.bg.ac.rs
Nikola
N
Tanic
Zorka
Z
Milovanovic
Nasta
N
Tanic
Radan
R
Dzodic
Zorica
Z
Juranic
Snezana
S
Susnjar
Vesna
V
Plesinac-Karapandzic
Svetislav
S
Tatic
Tatjana
T
Dramicanin
Radoslav
R
Davidovic
Bogomir
B
Dimitrijevic
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004967:Estrogens / Q000378:metabolism; D005260:Female; D016147:Genes, Tumor Suppressor; D006801:Humans; D019656:Loss of Heterozygosity; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism; D011379:Prognosis; D013629:Tamoxifen / Q000008:administration & dosage*; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics
D004967:Estrogens; D025521:Tumor Suppressor Proteins; D013629:Tamoxifen; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human